(n = 76) | Mean ± sd (Min-Max) | |
---|---|---|
Age (year) | 31.46 ± 8.75 (18–58) | |
Follow-up time (month) | 38.70 ± 25.62 (6–96) | |
n (%) | ||
Gender | Male | 51 (67.1) |
Female | 25 (32.9) | |
Uveitis type | Anterior | 16 (21.1) |
Posterior | 12 (15.7) | |
Panuveitis | 48 (63.2) | |
Laterality | Unilateral (right/left) | 36 (20/16) (47.4, 26.3/21.1) |
Bilateral | 40 (52.6) | |
HLAB51 | Positive | 8 (10.5) |
Negative | 5 (6.6) | |
Not performed | 63 (82.9) | |
Pathergy | Positive | 9 (11.8) |
Negative | 18 (23.7) | |
Not performed | 49 (64.5) | |
First line therapy | CS | 11 (14.5) |
CS + AZA | 58 (76.3) | |
CS + CsA | 1 (1.3) | |
CS + MTX | 1 (1.3) | |
CS + AZA + CsA | 4 (5.3) | |
IFNα2a | 1 (1.3) | |
Extraocular symptoms | Recurrent oral ulcers | 76 (100) |
Genital ulceration | 52 (68.4) | |
Folliculitis | 47 (61.8) | |
Arthritis | 41 (53.9) | |
Erythema Nodosum | 19 (25.0) | |
CNS involvement | 9 (11.8) | |
Thrombophlebitis | 4 (5.2) |